Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | MMP2 | P08253 | 5/20 | 0.50 |
| ▸ | MMP9 | P14780 | 2/20 | 0.50 |
| ▸ | MMP3 | P08254 | 1/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.47 |
| ▸ | MMP13 | P45452 | 3/20 | 0.47 |
| ▸ | ADAMTS5 | Q9UNA0 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MMP14 | P50281 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | SCN1A | P35498 | 1/20 | 0.39 |
| ▸ | SCN4A | P35499 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794277 | 0.81 | ALDH1A1 (0.51) | ALDH1A1MMP2MMP9MMP3ADAM17 | |
| SCHEMBL9047819 | 0.81 | ALDH1A1 (0.56) | ALDH1A1MMP2MMP9MMP3ADAM17 | |
| SCHEMBL7097777 | 0.78 | ALDH1A1 (0.60) | ALDH1A1MMP2MMP9ADAM17MMP13 | |
| SCHEMBL15972776 | 0.78 | ALDH1A1 (0.60) | ALDH1A1MMP2MMP9ADAM17MMP13 | |
| SCHEMBL1108471 | 0.78 | ALDH1A1 (0.52) | ALDH1A1MMP2MMP9MMP3ADAM17 | |
| SCHEMBL31721438 | 0.77 | ALDH1A1 (0.53) | ALDH1A1MMP2MMP9MMP3ADAM17 | |
| SCHEMBL17884976 | 0.77 | ADAMTS5 (0.62) | ALDH1A1MMP2ADAM17MMP13ADAMTS5 | |
| SCHEMBL12084968 | 0.77 | ALDH1A1 (0.59) | ALDH1A1MMP2MMP9ADAM17MMP13 | |
| SCHEMBL12084969 | 0.77 | ALDH1A1 (0.59) | ALDH1A1MMP2MMP9ADAM17MMP13 | |
| SCHEMBL9584263 | 0.76 | SMN1; SMN2 (0.68) | ALDH1A1MMP2MMP9ADAM17MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022249006-A1 | USE OF 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2022-12-01 | — | — | WO | disclosed |
| US-20220340573-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-10-27 | — | — | US | disclosed |
| EP-4065228-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS | Novartis AG (CH) | 2022-10-05 | — | — | EP | disclosed |
| US-11427586-B2 | 1,2,4-oxadiazole derivatives as liver X receptor agonists | NOVARTIS AG (CH) | 2022-08-30 | — | — | US | disclosed |
| CN-114746149-A | 1,2, 4-oxadiazole derivatives as liver X receptor agonists | 诺华股份有限公司 | 2022-07-12 | — | — | CN | disclosed |
| US-20220064164-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-03-03 | — | — | US | disclosed |
| WO-2021105857-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2021-06-03 | — | — | WO | disclosed |
| US-7989649-B2 | Tumor imaging compounds | EMORY UNIVERSITY (US) | 2011-08-02 | — | — | US | disclosed |
| US-20090240041-A1 | TUMOR IMAGING COMPOUNDS | EMORY UNIVERSITY (US) | 2009-09-24 | — | — | US | disclosed |
| US-7544715-B2 | Tumor imaging compounds | EMORY UNIVERSITY (US) | 2009-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064164-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS | NR1H4, GPBAR1, NR1I2 | ALDH1A1 368/4885MMP2 3336/4885MMP9 3561/4885 |
| US-20090240041-A1 | TUMOR IMAGING COMPOUNDS | AADAT, MKI67, SSTR1 | ALDH1A1 2290/4885MMP2 2917/4885MMP9 4220/4885 |
| US-11427586-B2 | 1,2,4-oxadiazole derivatives as liver X receptor agonists | NR1H4, GPBAR1, NR1I2 | ALDH1A1 368/4885MMP2 3336/4885MMP9 3561/4885 |
| US-20220340573-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS | NR1H4, GPBAR1, NR1I2 | ALDH1A1 368/4885MMP2 3336/4885MMP9 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.